

IUS Combined With VAT Predicts Anti-TNF- α Efficacy in Patients With IBD: a Prospective Study

NCT06165029

Status RECRUITING
Sponsor The Third Xiangya Hospital of Central South University
Enrollment 50 participants

Key Eligibility Criteria

Inclusion (5)

- Age e 18 years and d 80 years;
- Patients with newly diagnosed or relapsed active IBD;
- Anti-TNF- α monotherapy is proposed to be applied within 1 month after baseline endoscopy;
- No history of abdominal surgery;
- Clearly understand, voluntarily participate in the study, and sign an informed consent form.

Exclusion (3)

- Contraindications to anti-TNF- α therapy: allergy, active tuberculosis or other active infections, moderate-to-severe heart failure (NYHA grade III/IV), demyelinating lesions of the nervous system, live vaccination within the last 3 months, pregnancy and lactation;
- Patients with a history of extensive colectomy or recent proposed colectomy, history of colonic mucosal dysplasia;
- Hypersensitivity to the components of SonoVue contrast media.

Locations (1 total)

the Third Xiangya Hospital of Central South University, Changsha, Hunan, China